Completed Trials
63 articles
For Families at Risk, Remote Education May Be Key in Improving Genetic Testing Uptake
What’s the best way to educate families at risk for pancreatic cancer about genetic testing? Dr. Sapna Syngal discusses the results of the GENERATE study.
Progress in BRCA-Related Cancers Highlighted By the Basser Center
The Basser Center for BRCA hosted a panel discussion of the latest breakthroughs and discoveries for BRCA-related cancers.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
“Radical Collaboration” to Find Cures for the Deadliest Cancers
Break Through Cancer was founded to promote collaboration between major research institutions, in order to develop cures for the deadliest cancers.
Modifying the Tumor Microenvironment to Make Treatment More Effective
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Combining Two Drugs with Different Approaches to Enhance Treatment
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.
Precision Radiotherapy to Make Pancreatic Tumors Removable
A clinical trial tests a precision radiation technique called intensity-modulated radiation therapy against locally advanced pancreatic cancer.
A Novel Combination to Slow Pancreas Tumors that Cannot Be Surgically Removed
Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?
“Off-the-Shelf” Vaccine Improves Overall and Average Relapse Survival
Dr. Zev Wainberg provides an update on the effectiveness of a vaccine, with results showing it extends the time to relapse in many patients.
AACR Annual Meeting 2021 Highlights
Let’s Win and the Lustgarten Foundation bring you the pancreatic cancer research highlights of the 2021 AACR Annual Meeting,
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.